BioAdaptives Ships First XcellaraHeart Orders Marking Commercial Milestone

BioAdaptives, Inc. has announced the shipment of its first commercial orders for the XcellaraHeart™, marking a significant milestone in the company's transition from research and development to commercial execution. The move follows the retirement of major convertible debt and the cancellation of millions of shares by the CEO, signaling a strategic push for capital restructuring and sustainable growth.

Initial orders for XcellaraHeart™, part of the company’s Xcellara™ cellular wellness platform, will begin shipping next week. This product is designed to support cardiovascular and cellular energy. Alongside this, the company is preparing the second product in its pipeline, XcellaraResilience™, for a launch in October 2026. Four additional specialized formulations are currently in active research and development, aiming to complete a six-product suite.

Chief Executive Officer James E. Keener highlighted the significance of the first commercial orders: "Shipping our first commercial orders of XcellaraHeart is a decisive step forward. We are pairing this commercial momentum with aggressive balance sheet restructuring, eliminating major debt overhangs and retiring tens of millions of shares, to ensure we build sustainable value for our shareholders."

Keener also announced that he had voluntarily canceled and retired 43,250,000 common shares of BioAdaptives without compensation, reducing the total outstanding common share count. He noted, "Over the past two years, our primary objective has been building a disciplined foundation capable of turning scientific innovation into reliable, repeatable commercial execution."

In addition to product launches and share reductions, BioAdaptives is expanding its ambassador program. UFC Hall of Famer, podcaster, and entrepreneur Michael Bisping has been appointed as a paid brand ambassador for the MyndSystem™ cognitive performance and recovery platform. The MyndSystem platform is designed to support the daily cycle of mental stamina, focus, and restorative recovery, with products like MyndMed™ for daytime cognitive performance and MyndRenew™ for nighttime recovery.

Keener emphasized the company’s focus on driving reliable fulfillment, expanding distributor networks, and executing its MyndSystem marketing campaign. "Moving products out of the laboratory and into the hands of customers is where execution begins," he said.

The Xcellara™ platform targets specific organ systems and cellular health pathways, with XcellaraHeart™ being the first product to hit the market. The company’s flagship product, the Xcellara™ base formula, is backed by a human randomized, double-blind, placebo-controlled trial demonstrating a 268.8% increase in circulating hematopoietic stem and progenitor cells after four weeks, without negative effects on over twenty blood parameters. Additional formulas in the pipeline focus on areas such as heart, joints, nerves, skin, longevity, and stress resilience.

BioAdaptives organizes its product pipeline around two core commercial platforms: the Xcellara™ Platform, which includes XcellaraHeart™ and XcellaraResilience™, and the MyndSystem™ Platform, which includes MyndMed™ and MyndRenew™. These products are designed to support longevity, resilience, and performance.

While BioAdaptives continues to emphasize its commitment to scientific innovation and reliable commercial execution, it also warns that forward-looking statements in the release are subject to risks and uncertainties. The company's strategic moves underscore its dedication to building a sustainable foundation for long-term growth.